CERo Current Deferred Revenue from 2010 to 2026
| CERO Stock | 0.04 0 6.98% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 23.1 K | Current Value 24.3 K | Quarterly Volatility 570 K |
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 118.3 K, Interest Income of 118.3 K or Depreciation And Amortization of 961.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
CERo | Current Deferred Revenue | Build AI portfolio with CERo Stock |
Evaluating CERo Therapeutics's Current Deferred Revenue across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into CERo Therapeutics Holdings's fundamental strength.
Latest CERo Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of CERo Therapeutics Holdings over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. CERo Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
CERo Current Deferred Revenue Regression Statistics
| Arithmetic Mean | (697,468) | |
| Geometric Mean | 406,922 | |
| Coefficient Of Variation | (81.72) | |
| Mean Deviation | 490,872 | |
| Median | (1,045,169) | |
| Standard Deviation | 569,958 | |
| Sample Variance | 324.9B | |
| Range | 1.6M | |
| R-Value | 0.75 | |
| Mean Square Error | 154B | |
| R-Squared | 0.56 | |
| Significance | 0.0006 | |
| Slope | 84,123 | |
| Total Sum of Squares | 5.2T |
CERo Current Deferred Revenue History
About CERo Therapeutics Financial Statements
CERo Therapeutics investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how CERo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 23.1 K | 24.3 K |
Pair Trading with CERo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CERo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against CERo Stock
| 0.78 | DRTS | Alpha Tau Medical | PairCorr |
| 0.75 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.7 | VALN | Valneva SE ADR | PairCorr |
| 0.66 | GXEA | Galapagos NV | PairCorr |
| 0.65 | 6C1 | CytomX Therapeutics | PairCorr |
The ability to find closely correlated positions to CERo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CERo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CERo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CERo Therapeutics Holdings to buy it.
The correlation of CERo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CERo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CERo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CERo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of CERo Therapeutics Correlation against competitors. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Will Biotechnology sector continue expanding? Could CERo diversify its offerings? Factors like these will boost the valuation of CERo Therapeutics. Projected growth potential of CERo fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CERo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding CERo Therapeutics requires distinguishing between market price and book value, where the latter reflects CERo's accounting equity. The concept of intrinsic value - what CERo Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push CERo Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between CERo Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CERo Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, CERo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.